A Phase 2 interventional study of Capecitabine and Irinotecan in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 74th largest by enrollment of the 173 interventional ones that give a count, is one of 3 that started in 2001, is one of 100 in phase 2, and was the 4th registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Nizhny Novgorod Regional Clinical Oncology Center · Sites in Russian Federation
Ages 70–90
Henry Ford Health System · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 124 · Phase 3 37 · Phase 4 8
First in 1998; this study’s year is marked. 3 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is below the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 173 interventional studies. Of the 111 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 179 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 6 under way, none of them phase 3. Of 100 finished, 52 (52%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 44th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2001, is one of 32 in phase 2, and was the 2nd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
9 of the studies testing capecitabine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700656The Netherlands Cancer InstituteGalunisertib Combined With Capecitabine in Advanced CRC With PM | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT07051785Liu HuangFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | 2027-07-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
OBJECTIVES:
Primary:
Secondary:
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily on days 2-15 and irinotecan IV over 90 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients maintaining a response or stable disease after 12 courses may continue treatment at the discretion of the investigator.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study within 9 months.
DISEASE CHARACTERISTICS:
At least 1
PATIENT CHARACTERISTICS:
Age:
Performance status:
:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Gastrointestinal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive capecitabine (Xeloda) 1000 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
Drug: Capecitabine · Drug: Irinotecan
Participants will receive capecitabine 900 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
Drug: Capecitabine · Drug: Irinotecan
Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (\>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR.
Time frame: Approximately 43 Months
Time to Disease Progression
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available.
Time frame: Approximately 43 Months
Time to Treatment Failure
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent.
Time frame: Approximately 43 Months
Percentage of Participants With One-year Survival
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first.
Time frame: Up to Month 12
Overall Survival
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive.
Time frame: Approximately 43 Months
Time To Objective Response
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response.
Time frame: Approximately 43 Months
Duration of Overall Response
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment.
Time frame: Approximately 43 Months
Duration of Overall Complete Response
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment.
Time frame: Approximately 43 Months
Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.
Time frame: Approximately 43 Months
A total of 67 participants were enrolled in the study, which was conducted from 18 May 2001 to 9 December 2004 at 18 study centers in the United States.
| Milestone | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Started | 15 | 52 |
| Completed | 7 | 17 |
| Not completed | 8 | 35 |
| Withdrew: Adverse event | 5 | 9 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Failure to return | 0 | 1 |
| Withdrew: Refused treatment | 0 | 2 |
| Withdrew: Insufficient therapeutic response | 2 | 14 |
| Withdrew: Administrative /other | 1 | 7 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (\>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR.
| percentage of participants | Cohort 1, Initial Regimen:(Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| CR | 7 | 2 |
| PR | 40 | 42 |
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Time to Disease Progression | 6.1 (3.4 to 9.0) | 7.6 (5.8 to 8.7) |
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Time to Treatment Failure | 5.8 (2.4 to 9.2) | 7.3 (4.6 to 9.5) |
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first.
| percentage of participants | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Percentage of Participants With One-year Survival | 67 (43 to 91) | 71 (58 to 83) |
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Overall Survival | 22.9 (10.1 to 28.2) | 20.5 (14.9 to 30.0) |
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Time To Objective Response | 5.5 (2.7 to 8.6) | 4.3 (2.6 to 9.6) |
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Duration of Overall Response | 7.0 (2.6 to 9.2) | 7.7 (5.8 to 11.5) |
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment.
| months | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| Duration of Overall Complete Response | 12.45 | 12.68 |
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.
| Number of participants | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | Total Participants (Cohort 1 + Cohort 2) |
|---|---|---|---|
| Any AEs | 15 | 52 | 67 |
| SAEs | 10 | 25 | 35 |
| Deaths During Study | 0 | 3 | 3 |
| Deaths During Follow-up | 13 | 23 | 36 |
Collected over Approximately 43 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | — | 10/15 (66.7%) | 15/15 (100%) |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | — | 25/52 (48.1%) | 52/52 (100%) |
| Event | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 3/15 | 4/52 |
| DiarrhoeaGastrointestinal disorders | 2/15 | 5/52 |
| Deep vein thrombosisVascular disorders | 2/15 | 3/52 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/15 | 2/52 |
| Small intestinal obstructionGastrointestinal disorders | 0/15 | 6/52 |
| ColitisGastrointestinal disorders | 1/15 | 0/52 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/15 | 0/52 |
| PneumoniaInfections and infestations | 1/15 | 0/52 |
| SepsisInfections and infestations | 1/15 | 0/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/15 | 1/52 |
| Event | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 13/15 | 45/52 |
| NauseaGastrointestinal disorders | 13/15 | 34/52 |
| FatigueGeneral disorders | 8/15 | 32/52 |
| VomitingGastrointestinal disorders | 7/15 | 26/52 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 7/15 | 24/52 |
| Abdominal painGastrointestinal disorders | 6/15 | 24/52 |
| AnaemiaBlood and lymphatic system disorders | 6/15 | 18/52 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/15 | 18/52 |
| ConstipationGastrointestinal disorders | 5/15 | 17/52 |
| NeutropeniaBlood and lymphatic system disorders | 5/15 | 16/52 |
The All Patients Population included participants who received at least one dose of study drug in Cohort 1 or Cohort 2.
| Age, Continuous(years) | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | Total |
|---|---|---|---|
| Mean | 63.1 ± 8.3 | 61.4 ± 11.1 | 61.8 ± 10.5 |
| Sex: Female, Male(Participants) | Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | Total |
|---|---|---|---|
| Female | 9 | 21 | 30 |
| Male | 6 | 31 | 37 |
The record gives a start of May 2001, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 11 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Irinotecan